Speaker Profile

Vice President, Real-World Data & Analytics, Ontada

Biography
Dr. Chandrasekaran has over 15 years of pharmaceutical industry experience at the intersection of data science, RWD and drug discovery/development. He joined Ontada in 2021 and has responsibility for the development, delivery and growth of data products and data science offerings to biopharma clients seeking to leverage real-world data across the discovery, development and commercialization lifecycle. Prior to joining Ontada, he spent 5 years at Merck & Co. where he led a data science team responsible for data science capabilities and strategy. Before Merck, Dr. Chandrasekaran held positions of increasing responsibilities at UMass Medical School, Cubist and Novartis. Dr. Chandrasekaran obtained his Ph.D. in structural bioinformatics from the University of Georgia and completed postdoctoral fellowships at UNC-Chapel Hill and MIT prior to joining the pharmaceutical industry. He has published in several peer-reviewed journals and presented at scientific meetings, including the American Medical Informatics Association (AMIA) and Observational Health Data Sciences and Informatics (OHSDI).


 Session Abstract – PMWC 2023 Silicon Valley

Track 2 - January 26 9.00 A.M.-4.30 P.M.


Track Chair: - Courtney McFall, UCSF
- Ben Rubin, UCSF

Patient-centric data – Real-World Evidence (RWE) and Real-World Data (RWD) - is becoming instrumental in the drug development process and for health care decisions in general. This data is not only informative for the process from discovery to new indications, clinical trial design, and drug development, it also can be of value to monitor post-marketing drug safety and for decision support in clinical practice. As the data becomes a decision driver, science companies and medical organizations are increasingly focused on leveraging RWD and RWE to not only better understand the patient populations using their drugs and the respective outcomes, but also to accelerate clinical decision support. This session will focus on the various aspects of integrating RWE and RWD to support drug development and clinical decision support.

Sessions:

  • Clinical Studies Using RWD (PANEL)
    Chair:
    - Liora Schultz, Stanford
    - Sanket Dhurva, UCSF
    - Eze Abosi, Optum Life Sciences
    - Motiur Rahman, FDA
    - Aaron Kamauu, Navidence
  • Beyond the EHR: Acquisition of RWD Types to Enable Precision Medicine (PANEL)
    Chair: Riley Bove, UCSF
    - Anna Berry, Sypase
    - Ashley Brenton, Optum
    - Vasu Chandrasekaran, Ontada
  • Data Linkage, Harmonization, and Quality (PANEL)
    Chair: Vivek Rudrapatna, UCSF
    - Rohit Vashisht, UCSF
    - Adam Asare, QLHC
    - Dan Riskin, Verantos
    - Wanmei Ou, Ontada
    - Mindy DeRouen, UCSF
    - Saurabh Gombar, Atropos Health
  • Using RWE to Uncover and Address Health Disparities (PANEL)
    Chair: Chris Boone, AbbVie
    - Robert Hiatt, UCSF
    - Abasi Ene-Obong, 54gene
    - Nuray Yurt, Novartis Oncology
    - Alice Popejoy, UC Davis Health
    - Vic Spain, Genentech
  • FDA RWD/RWE Draft and Final Guidances
    - Motiur Rahman, FDA
  • From Real-World Data to Regulatory-Grade Real-World Evidence
    Chair: Sheila Walcoff, Goldbug Strategies
  • Session TBA
    Chair: Speaker TBA, Ample